
TLX P/E Ratio
P/E Ratio as of Jan 9, 2026: 227.71
Average243.04
Median236.14
Minimum224.70
Maximum298.80
227.71
62.05 (21.41%)past month
The P/E ratio for TLX is 227.71 as of Jan 9, 2026. This represents a increase of 4.92% compared to its 12-month average P/E ratio of 217.04. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Telix Pharmaceuticals Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Telix Pharmaceuticals Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Telix Pharmaceuticals Ltd to industry peers.
Telix Pharmaceuticals Ltd P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Telix Pharmaceuticals Ltd’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Telix Pharmaceuticals Ltd to industry peers.
TLX P/E Ratio Insights
See Telix Pharmaceuticals Ltd’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares
TLX P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $9.82 | 295.78 |
| Nov 3, 2025 | $10.39 | 312.95 |
| Oct 1, 2025 | $10.17 | 306.33 |
| Sep 2, 2025 | $9.43 | 284.04 |
| Aug 1, 2025 | $13.05 | 131.02 |
| Jul 1, 2025 | $16.08 | 161.45 |
| Jun 2, 2025 | $16.8077 | 168.75 |
| May 1, 2025 | $17.94 | 180.12 |
| Apr 1, 2025 | $16.71 | 167.77 |
| Mar 3, 2025 | $18.045 | 181.17 |
| Feb 3, 2025 | $18.36 | 185.64 |
| Jan 2, 2025 | $15.00 | 151.67 |
TLX End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | 227.71 | +0.94% |
| 2025 | 225.60 | +44.88% |
| 2024 | 155.71 | — |
FAQs About Telix Pharmaceuticals Ltd (TLX) P/E ratio
The latest P/E ratio of TLX is 227.71, as of Jan 9, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Telix Pharmaceuticals Ltd’s last 12-month average P/E ratio is 217.04, compared to its current P/E ratio of 227.71. This reflects a increase of 4.92%.
Telix Pharmaceuticals Ltd’s current P/E ratio of 227.71 is higher than its last 12-month average P/E of 217.04. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Telix Pharmaceuticals Ltd’s average P/E ratio over the last 3 years is 85.36. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Telix Pharmaceuticals Ltd’s average P/E ratio over the last 5 years is 51.22. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.